CLAIM AMENDMENTS

Before claim 1 please replace "Claims" with - WHAT IS CLAIMED IS: - -

1. (Currently amended) ~~Avipoxvirus~~ An avipoxvirus grown in avian cells, comprising in the viral genome a Vaccinia virus host range gene selected from the group consisting of C18L, C17L, C7L, K1L, E3L, B4R, B23R, and B24R or a homologue of said host range gene and having an increased viral titer compared to that of a corresponding avipoxvirus without said Vaccinia virus host range gene added to said viral genome ~~, with the proviso that the host range gene is not the E3L gene if the avipoxvirus is a recombinant canarypoxvirus comprising in the viral genome the Vaccinia virus K3L gene as well as expression cassettes for HIV gag-pro, gp120/TM and a Nef/Pol poly-epitope string, respectively~~.

2. (Currently amended) Avipoxvirus grown in avian cells according to claim 1, wherein the Vaccinia virus host range gene is a host range gene for human cells.

3. (Currently amended) Avipoxvirus grown in avian cells according to claim 1 or claim 2, wherein the host range gene is selected from the Vaccinia virus genes E3L, C7L and K1L.

4. (Currently amended) Avipoxvirus grown in avian cells according to claim 1,selected from the group consisting of Fowlpoxvirus and Canarypoxvirus.

5. (Currently amended) Avipoxvirus grown in avian cells according to claim 1 comprising in the viral genome at least one additional heterologous nucleic acid sequence.

6. (Currently amended) Avipoxvirus grown in avian cells according to claim 5, wherein the additional heterologous nucleic acid sequence is selected from a sequence coding for at least one antigen, antigenic epitope, and/or a therapeutic compound.

7. (Currently amended) Pharmaceutical composition comprising the avipoxvirus grown in avian cells according to claim 1 and a pharmaceutically acceptable carrier, diluent and/or additive.

8. (Currently amended) Vaccine comprising the avipoxvirus grown in avian cells according to claim 1.

9. (Currently amended) The [[virus]] avipoxvirus grown in avian cells according to claim 1, as drug for effecting an immunological response in a living animal, including a human.

10. (Canceled)

11. (Withdrawn) Method for introducing a homologous and/or a heterologous nucleic acid sequence into target cells comprising the infection of the target cells with the virus according to claim 5 or claim 6.

12. (withdrawn) Method for producing a peptide, protein and/or virus comprising the steps of infection of a host cell with the virus according to claim 1, claim 5 or claim 6, cultivation of the infected host cell under suitable conditions, and isolation and/or enrichment of the peptide and/or protein expressed from the viral genome and/or of the virus produced by said host cell.

13. (withdrawn) Method for effecting an immunological response in a living animal body including a human comprising administering the virus according to claim 1, claim 5 or claim 6 to the animal or human to be treated.

14. (withdrawn) The method according to claim 13, wherein the animal is immuno compromised.

15. (Currently amended) [[A]] An isolated avian cell containing the [[virus]] avipoxvirus grown in avian cells according to claim 1, claim 5 or claim 6.

16. (withdrawn) Method for obtaining the avipoxvirus according to claim 1 comprising the following steps:
- introducing an avipoxvirus genome and a DNA comprising a Vaccinia virus host range gene or a homologue of said host range gene, with the proviso that the host range gene is not the E3L gene if the avipoxvirus is a recombinant canarypoxvirus comprising in the viral genome the Vaccinia virus K3L gene as well as expression cassettes for HIV gag-pro, gp120/TM and a Nef/Pol poly-epitope string,

respectively into cells in which the virus is able to reproductively replicate, wherein the DNA is capable to specifically recombine with the genomic DNA of the avipoxvirus-isolating/enriching virus particles comprising the host range gene in the viral genome from these cells.

17. (Withdrawn) Method for obtaining the avipoxvirus according to claim 5 or claim 6, comprising the following steps:
- introducing the genome of an avipoxvirus comprising in the viral genome a Vaccinia virus host range gene or a homologue of said host range gene, with the proviso that the host range gene is not the E3L gene if the avipoxvirus is a recombinant canarypoxvirus comprising in the viral genome the Vaccinia virus K3L gene as well as expression cassettes for HIV gag-pro, gp120/TM and a Nef/Pol poly-epitope string, respectively and a DNA comprising the at least one additional heterologous sequence into cells in which the virus is able to reproductively replicate, wherein the DNA is capable to specifically recombine with the genomic DNA of the avipoxvirus
- isolating/enriching virus particles comprising the at least one additional heterologous sequence in the viral genome from these cells.

18. (Currently amended) ~~Cell, in particular an~~ An isolated avian cell, infected with an avipoxvirus grown in avian cells and a Vaccinia virus, wherein the Vaccinia virus comprises at least one Vaccinia host range gene selected from the group consisting of C18L, C17L, C7L, K1L, E3L, B4R, B23R, and B24R or a homologue thereof in the viral genome and wherein the avipoxvirus has an increased viral titer over that of a corresponding avipoxvirus without said Vaccinia virus host range gene added to said viral genome.

19. (Currently amended) ~~Cell, in particular an~~ An isolated avian cell, comprising a Vaccinia virus host range gene selected from the group consisting of C18L, C17L, C7L, K1L, E3L, B4R, B23R, and B24R or a homologue of said host range gene, wherein the host range gene or the homologue of said host range gene is not part of a Vaccinia virus genome ~~, with the proviso that the host range gene is not the E3L gene~~.

20. (Currently amended) [[Cell]] An isolated avian cell according to claim 18 or claim 19, wherein the host range gene is a Vaccinia virus host range gene selected from the group consisting

of E3L, C7L, K1L, or a homologue of said host range gene ~~,with the proviso that the host range gene is not the E3L gene if the avipoxvirus is a recombinant canarypoxvirus comprising in the viral genome the Vaccinia virus K3L gene as well as expression cassettes for HIV gag-pro, gp120/TM and a Nef/Pol poly-epitope string, respectively for human cells~~.

21. (Currently amended) [[Cell]] An isolated avian cell according to claim 20, wherein the host range gene is integrated in the cellular genome.

22. (Currently amended) [[Cell]] An isolated avian cell according to claim 20, wherein the host range gene is part of a non-integrated DNA.

23. (Currently amended) [[Cell]] An isolated avian cell according to claim [[20]] 19, infected with an avipoxvirus grown in avian cells.

24. (Currently amended) [[Cell]] An avian cell according to claim 23, wherein the avipoxvirus grown in avian cells is a recombinant avipoxvirus.

25. (Currently amended) [[Cell]] An avian cell according to claim 23, wherein the host range gene or the homologue of said host range gene is not part of the genome of the Avipoxvirus.

26. (Currently amended) [[Cell]] An avian cell according to claim 15, wherein the cells allow the reproductive replication of the avipoxvirus.

27. (Canceled)

28. (Withdrawn) Method for increasing the titer of avipoxviruses by infecting cells as defined in claim 19, claim 20, claim 21 or claim 22 with said avipoxvirus, wherein the cells are cells allowing the productive replication of the avipoxvirus.

29. (withdrawn) Method for increasing the titer of avipoxviruses by cultivating cells as defined in claim 15, wherein the cells are cells allowing the productive replication of the avipoxvirus.

30. (withdrawn) Method for increasing the titer of avipoxviruses by cultivating cells as defined in claim 18, claim 23, claim 24 or claim 25 wherein the cells are cells allowing the productive replication of the avipoxvirus.

31. (Currently amended) Avipoxvirus grown in avian cells according to claim 1 or claim 2, wherein the host range gene is Vaccinia virus gene C7L.